519 related articles for article (PubMed ID: 16268466)
1. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
2. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Harenberg J; Ingrid J; Tivadar F
Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
11. The role of ximelagatran in the treatment of venous thromboembolism.
Schulman S
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
[TBL] [Abstract][Full Text] [Related]
12. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
14. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Harenberg J; Jörg I; Weiss C
Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
16. [Ximelagatran for treatment of venous thromboembolism].
Harenberg J; Fenyvesi T; Jörg I
Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
[TBL] [Abstract][Full Text] [Related]
17. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
18. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Colwell CW; Berkowitz SD; Lieberman JR; Comp PC; Ginsberg JS; Paiement G; McElhattan J; Roth AW; Francis CW;
J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran: an oral direct thrombin inhibitor.
Dager WE; Vondracek TG; McIntosh BA; Nutescu EA
Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
